Cerus Corporation

Cerus Corporation is a biomedical products company focused on enhancing blood safety through its proprietary INTERCEPT Blood System technology. The company develops and commercializes systems designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its main products include INTERCEPT Blood Systems for platelets, plasma, and cryoprecipitation, which inactivate pathogens in these components. Additionally, Cerus has an INTERCEPT Blood System for red blood cells and an INTERCEPT Illuminator, an LED-based device used for blood component treatment. The company sells its platelet and plasma systems through a direct sales force and distributors globally.

Cerus Corporation is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol CERS. Its shares are traded in US dollars (USD). The company is headquartered in Concord, California, and operates primarily in the United States, though it sells its products globally through direct sales and distributor networks.

Cerus Corporation operates in the Healthcare sector and is classified under the Medical Devices industry. As a biomedical products company, it focuses on developing technologies for blood safety, specifically the INTERCEPT Blood System, which is used to inactivate pathogens in donated blood components. This places it within the medical device subsector that deals with blood transfusion and pathogen reduction technologies.

Cerus Corporation is headquartered in Concord, California, United States. The company serves global markets, selling its INTERCEPT Blood System for platelets and plasma through a direct sales force and distributors worldwide. Its technology is used in blood centers and hospitals to enhance the safety of blood transfusions by reducing the risk of transfusion-transmitted infections.

Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California. The company was formerly known as CERUS TECHNOLOGIES INC before rebranding to Cerus Corporation in July 1996. Since its founding, Cerus has focused on developing and commercializing the INTERCEPT Blood System to improve blood safety. The company's technology is designed to control biological replication and reduce blood-borne pathogens in donated blood components, including platelets, plasma, and red blood cells.